GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

About this update from Strategic Partners A/s

[{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 20, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the publication of its 2026 extra-financial performance report (fiscal year 2025), available on its website.","length":366,"tagName":"p"},{"type":"text","content":"Since 2022, GENFIT has published a detailed report in response to the growing interest of institutional and individual shareholders, financial analysts, ESG analysts, the Company’s employees and prospective candidates, industrial and strategic partners, as well as public institutions.","length":285,"tagName":"p"},{"type":"text","content":"Pascal Prigent, Chief Executive Officer of GENFIT, stated: “Collective engagement, dialogue with external stakeholders, rigor and ethical practices, as well as effective risk management, are inseparable from GENFIT’s ability to execute its strategy while maintaining trust with its stakeholders. These fundamentals are what make our operational and clinical progress possible, with a clear objective: delivering tangible benefits to patients. In 2025, the execution of our ESG roadmap and the achievement of B Corp™ certification confirmed the robustness of this approach, which helps create the conditions for the Company’s long-term performance.”","length":648,"tagName":"p"},{"type":"text","content":"In 2025, GENFIT implemented the ESG roadmap defined at the beginning of the year and rolled out around 30 initiatives involving all employees.","length":142,"tagName":"p"},{"type":"text","content":"From a societal perspective, actions focused on the coordinated mobilization of the medical, scientific, industrial and regulatory ecosystem, with the aim of positioning ACLF among strategic priorities and contributing to the acceleration of access-to-innovation pathways for patients with the greatest unmet needs. A full day dedicated to ACLF, bringing together all major international learned societies, will open the next EASL Congress. In addition, ACLF is now formally recognized as a strategic area of work by The Forum for Collaborative Research1, with the launch of a dedicated working group.","length":601,"tagName":"p"},{"type":"text","content":"From a social standpoint, the annual anonymous e...

More updates from Strategic Partners A/s